Home » Stocks » NVTA

Invitae Corporation (NVTA)

Stock Price: $27.08 USD -2.87 (-9.58%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $25.56 -1.52 (-5.61%) May 11, 8:45 AM
Market Cap 5.41B
Revenue (ttm) 318.97M
Net Income (ttm) -613.14M
Shares Out 194.00M
EPS (ttm) -3.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $27.08
Previous Close $29.95
Change ($) -2.87
Change (%) -9.58%
Day's Open 28.78
Day's Range 26.93 - 29.00
Day's Volume 6,375,862
52-Week Range 15.12 - 61.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Invitae (NVTA) closed at $29.95 in the latest trading session, marking a +1.66% move from the prior day.

3 days ago - Zacks Investment Research

Invitae CEO on the importance of genetic testing for preventative care

YouTube video

Invitae CEO Sean George joins "Power Lunch" to discuss genetic testing and what health care looks like after the pandemic.

5 days ago - CNBC Television

Invitae Corp (NYSE: NVTA) reported first-quarter FY21 results after the market closed Tuesday, wherein EPS loss of $0.63 came in worse than expectation of $0.59, sales of $103.6 million (+61% Y/Y) manag...

5 days ago - Benzinga

Sales were strong, but the medical genetics company still missed analysts' bottom-line expectations.

6 days ago - The Motley Fool

Invitae (NVTA) delivered earnings and revenue surprises of -5.00% and 1.58%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Shares of Invitae (NYSE:NVTA) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 21.25% over the past year to ($0.63), which missed the es...

6 days ago - Benzinga

SAN FRANCISCO, May 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 202...

6 days ago - PRNewsWire

More than 1,500 publicly traded companies are scheduled to report March quarter earnings this week, with heavy representation from energy exploration and production companies.

Other stocks mentioned: ATVI, DVN, LYFT, SKLZ
1 week ago - 24/7 Wall Street

Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.

1 week ago - Zacks Investment Research

Invitae (NVTA) closed at $36.66 in the latest trading session, marking a -1.5% move from the prior day.

1 week ago - Zacks Investment Research

Invitae Corporation (NVTA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

2 weeks ago - Zacks Investment Research

Invitae (NVTA) closed at $35.96 in the latest trading session, marking a -0.39% move from the prior day.

2 weeks ago - Zacks Investment Research

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced its plans to open a new laboratory and production facility in North Ca...

2 weeks ago - PRNewsWire

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2021 financial results on Tuesda...

3 weeks ago - PRNewsWire

WASHINGTON, April 19, 2021 /PRNewswire/ -- The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NY...

3 weeks ago - PRNewsWire

Can this leading clinical gene testing company add muscle to your portfolio?

3 weeks ago - The Motley Fool

SAN FRANCISCO, April 15, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced research showing one in six people with colorectal cancer harbor genet...

3 weeks ago - PRNewsWire

We're really excited that these genomics companies, says Ark's Simon Barnett

YouTube video

Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.

Other stocks mentioned: ADPT, ARKG, PACB
4 weeks ago - CNBC Television

All three companies have enjoyed major growth catalysts since the start of 2021.

Other stocks mentioned: AMRN, NNOX
1 month ago - The Motley Fool

SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Hum...

1 month ago - PRNewsWire

In an announcement on Monday, Invitae Corp (NYSE: NVTA) said it will receive £830 million investment from several investors, including the Japanese multinational conglomerate holding company, SoftBank G...

Other stocks mentioned: SFTBY
1 month ago - Invezz

Invitae Corp (NYSE: NVTA) has agreed to acquire Genosity Inc, a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests. De...

1 month ago - Benzinga

A group of investors including SoftBank Group Corp will invest $1.15 billion in Invitae Corp, the U.S. genetic diagnostics company said on Monday.

Other stocks mentioned: SFTBY
1 month ago - Reuters

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a...

1 month ago - PRNewsWire

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Management, a subsidiary of Softbank Gro...

1 month ago - PRNewsWire

Japanese technology firm SoftBank Group Corp (OTC: SFTBY) (OTC: SFTBF) is planning to infuse around $1.2 billion via convertible debt into genetic-testing provider Invitae Corp (NYSE: NVTA), the Wall St...

Other stocks mentioned: SFTBY
1 month ago - Benzinga

Eli Casdin on looking for opportunity in life sciences

YouTube video

Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.

Other stocks mentioned: FATE, XLV
1 month ago - CNBC Television

SAN FRANCISCO, April 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the availability of sponsored genetic testing for patients in the U.S.,...

1 month ago - PRNewsWire

AI applications will only increase as the world gets more efficient and these companies hope to take advantage.

Other stocks mentioned: GOOG, GOOGL, MDLA
1 month ago - The Motley Fool

Invitae (NVTA) closed the most recent trading day at $34.45, moving -0.61% from the previous trading session.

1 month ago - Zacks Investment Research

Blame a broader market sell-off of growth stocks.

1 month ago - The Motley Fool

It definitely could have more upside potential.

1 month ago - The Motley Fool

These two genetic testing companies have different approaches.

Other stocks mentioned: FLGT
1 month ago - The Motley Fool

Invitae CEO on the opportunity and competition in genetic testing

YouTube video

Ark Invest's Cathie Wood called genetic testing firm Invitae an underappreciated stock last week in a CNBC interview. Sean George, Invitae CEO, joins 'Closing Bell' to discuss the company's mission, the...

1 month ago - CNBC Television

The company unveiled its inaugural ESG report. But the overall rise in growth stocks was its main catalyst.

1 month ago - The Motley Fool

Invitae (NVTA) closed the most recent trading day at $38.66, moving -0.46% from the previous trading session.

1 month ago - Zacks Investment Research

SAN FRANCISCO, March 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the issuance of its inaugural Environmental, Social and Governance (ES...

2 months ago - PRNewsWire

A Relative Strength Rating upgrade for Invitae shows improving technical performance. Will it continue?

2 months ago - Investors Business Daily

Cathie Wood's recent comments on CNBC's 'Closing Bell' concerning Invitae (NVTA) stock have shares soaring higher on Tuesday. The post NVTA Stock: The Cathie Wood Comments That Have Invitae Shares Surgi...

2 months ago - InvestorPlace

Cathie Wood says Invitae is an under-appreciated stock

YouTube video

Cathie Wood, ARK Invest CEO, says one of the most under-appreciated stocks is Invitae, a company which offers medical genetic testing. She joins 'Closing Bell' to discuss.

2 months ago - CNBC Television

Top-line growth should help the company grow its bottom line eventually.

2 months ago - The Motley Fool

The overall market sell-off dragged Invitae's shares down.

2 months ago - The Motley Fool

SAN FRANCISCO, March 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31s...

2 months ago - PRNewsWire

The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.

2 months ago - The Motley Fool

The medical genetics company was pulled down by a broader sell-off of growth stocks.

2 months ago - The Motley Fool

SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its...

2 months ago - PRNewsWire

The healthcare company is diving along with the market.

2 months ago - The Motley Fool

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinic...

2 months ago - PRNewsWire

There's nothing to be alarmed about.

2 months ago - The Motley Fool

With the trading day more than halfway over, the broad markets were trading lower with the Dow down about 0.4 while the S&P 500 traded down about 0.5% and Nasdaq traded down nearly 0.9%.

Other stocks mentioned: MU, STX
2 months ago - 24/7 Wall Street

About NVTA

Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 12, 2015
Stock Exchange
NYSE
Ticker Symbol
NVTA
Full Company Profile

Financial Performance

In 2020, NVTA's revenue was $279.60 million, an increase of 28.95% compared to the previous year's $216.82 million. Losses were -$602.17 million, 148.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for NVTA stock is "Buy." The 12-month stock price forecast is 47.40, which is an increase of 75.04% from the latest price.

Price Target
$47.40
(75.04% upside)
Analyst Consensus: Buy